Compound ID | 607
Caprazamycin E
Class: Natural product antibiotic
| Agent Type: | Natural product; Direct acting; |
| Spectrum of activity: | Antimycobacterial |
| Mechanism of action: | Mycolic acid synthesis inhibitor. MraY inhibitor; interferes with cell-wall synthesis by inhibiting transfer of the peptidoglycan precursor moiety (MurNAc-pentapeptide) to the membrane lipid carrier, undecaprenyl phosphate |
| Target Pathogen: | Active against Mycobacterium tuberculosis |
| Description: | Natural product from Streptomyces sp. |
| Institute where first reported: | Meiji Seika Kaisha, Japan |
| Year first mentioned: | 2002 |
| Development status: | Experimental |
| Reason dropped: | IV only; modest anti-tubercular activity, low intracellular activity. Not great in vivo activity. Many analogues made. Permeability and efflux problems |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/139583924 |
| Citations: |
|
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.